40 results
-
List item
National expert: Othmar Engelhardt, European Medicines Agency (updated)
- Declaration of interests - 81.67 KB | PDF
- Curriculum Vitae - 30.32 KB | PDF
A. Trkola, P. Schulz, A. Grassauer, O. G. Engelhardt, A. Garcia-Sastre … -
List item
National expert: Ines Lindner, Austrian Medicines and Medical Devices Agency (updated)
- Declaration of interests - 79.78 KB | PDF
- Curriculum Vitae - 17.87 KB | PDF
Meier C, Url A., Unger H., Grassauer A., Prieschl Grassauer E., Doerfler P. Beta-escin hast … -
List item
National expert: Jeroen Dekervel, Federal Agency for Medicines and Health Products (updated)
- Declaration of interests - 81.49 KB | PDF
- Curriculum Vitae - 23.29 KB | PDF
Putter, R., Lambertini, M., Toss, A., Han, S., Van Nieuwenhuysen … -
List item
National expert: Monica Bartolomei, Italian Medicines Agency (updated)
- Declaration of interests - 79.89 KB | PDF
- Curriculum Vitae - 24.27 KB | PDF
-
List item
National expert: Maria Grazia Evandri, Italian Medicines Agency (updated)
- Declaration of interests - 79.83 KB | PDF
- Curriculum Vitae - 26.36 KB | PDF
-
List item
National expert: Kevin Punie, Federal Agency for Medicines and Health Products (updated)
- Declaration of interests - 87.31 KB | PDF
- Curriculum Vitae - 37.86 KB | PDF
-
List item
Human medicine European public assessment report (EPAR): SomaKit TOC (updated)
edotreotide, Neuroendocrine Tumors; Radionuclide Imaging
Date of authorisation: 08/12/2016,
, Revision: 14, Authorised, Last updated: 07/03/2023
-
List item
National expert: Leonard van den Berg, European Medicines Agency (updated)
- Declaration of interests - 84.99 KB | PDF
- Curriculum Vitae - 28.38 KB | PDF
I Corti S, Chio A, Calvo A, Grassano M, Beghi E, Logroscino G … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel/Acetylsalicylic acid Teva
clopidogrel, acetylsalicylic acid, Acute Coronary Syndrome; Myocardial Infarction
Date of authorisation: 01/09/2014, Revision: 1, Withdrawn, Last updated: 28/04/2017 -
List item
National expert: Rolf Gedeborg, Medical Products Agency (updated)
- Declaration of interests - 80.21 KB | PDF
- Curriculum Vitae - 30.46 KB | PDF
-
List item
National expert: Emilio Perucca, Italian Medicines Agency (updated)
- Declaration of interests - 85.84 KB | PDF
- Curriculum Vitae - 116.29 KB | PDF
TEGGIA DROGHI, M. Studio tossicologico dell'associazione trimethoprim-sulfametossipirazina … -
List item
National expert: Caridad Pontes, The Spanish Agency Of Medicines And Medical Devices (updated)
- Declaration of interests - 80.92 KB | PDF
- Curriculum Vitae - 49.74 KB | PDF
-
List item
Referral: Ambroxol and bromhexine-containing medicines
ambroxol, bromhexine, Article 31 referrals
Status: European Commission final decision, opinion/position date: 18/11/2015, EC decision date: 14/01/2016, Last updated: 05/02/2016 -
List item
Referral: Protium
pantoprazole, associated names: Anagastra, Apton, Controloc, Eupantol, Inipomp, Pantec, Pantecta, Pantipp, Panto-Byk-20 / 40 / IV, Pantoc, Pantoloc, PantoLomberg, Pantopan, Pantorc, Pantozol, Peptazol, Rifun, Somac, Ulcotenal, Zurcal, Zurcale, Zurcazol, Article 30 referrals
Status: European Commission final decision, opinion/position date: 17/12/2009, EC decision date: 15/04/2010, Last updated: 17/01/2012 -
List item
Referral: Pholcodine
pholcodine, Article 31 referrals
Status: European Commission final decision, opinion/position date: 15/12/2011, EC decision date: 17/02/2012, Last updated: 28/03/2012 -
List item
Orphan designation: recombinant human interleukin-3 truncated diphtheria toxin fusion protein for: Treatment of acute myeloid leukaemia
Date of designation: 09/10/2015, Positive, Last updated: 25/04/2022 -
List item
Orphan designation: Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein for: Treatment of cutaneous T-cell lymphoma
Date of designation: 09/08/2012, Positive, Last updated: 04/02/2022 -
List item
Orphan designation: Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein for: Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)
Date of designation: 09/08/2012, Positive, Last updated: 04/02/2022 -
List item
Orphan designation: Human monoclonal antibody targeting Staphylococcus aureus alpha-toxin (tosatoxumab) for: Treatment of pneumonia caused by Staphylococcus aureus
Date of designation: 05/03/2012, Positive, Last updated: 13/07/2021monoclonale umano contro la tossina alfa di Staphylococcus aureus … -
List item
Orphan designation: recombinant human interleukin-3 truncated diphtheria toxin fusion protein for: Treatment of blastic plasmacytoid dendritic cell neoplasm
Date of designation: 11/11/2015, Positive, Last updated: 25/01/2021 -
List item
Orphan designation: Carboxypeptidase G2 (glucarpidase) for: Adjunctive treatment in patients at risk of methotrexate toxicity
Date of designation: 03/02/2003, Positive, Last updated: 20/01/2022 -
List item
Orphan designation: Chimeric monoclonal antibody to shiga toxin 1 and 2 for: Treatment of shiga-toxin-producing bacterial infection
Date of designation: 26/08/2005, Positive, Last updated: 12/04/2019 -
List item
Orphan designation: Recombinant modified ricin toxin A-chain subunit for: Prevention of ricin poisoning
Date of designation: 21/03/2018, Positive, Last updated: 08/06/2020Subunità della catena A della tossina della ricina modificata … -
List item
National expert: Paola Minghetti, Italian Medicines Agency (updated)
- Declaration of interests - 81.41 KB | PDF
- Curriculum Vitae - 62.13 KB | PDF
-
List item
Orphan designation: Equine immunoglobulin F(ab')2 fragments targeting Shiga toxin for: Prevention of haemolytic uraemic syndrome
Date of designation: 25/05/2018, Positive, Last updated: 24/07/2018